Non-dilutive funding for biotech companies

Non-dilutive funding strategy for biotech companies.

Scientific and strategic support for biotech companies pursuing NIH SBIR/STTR and other non-dilutive funding opportunities. Evaluate funding fit, strengthen reviewer readiness, interpret feedback, and make better decisions about what to pursue next.

Discuss your funding strategy Explore services

Funding fit · Pre-submission review · Resubmission strategy · Advisory

Life-science PhD leadership
11 years directing independent biomedical research
$3M+ in NIH funding as PI
Grant-review experience across four U.S. and European funding agencies

Strategy-led services

From funding fit
to final review.

Support for funding decisions before, during, and after a submission. Evaluate the opportunity, identify weaknesses, interpret feedback, and determine what to do next.

Funding fit & go/no-go assessment

Evaluate program fit, mechanism, eligibility, scientific maturity, competitive positioning, and whether the opportunity warrants your company’s time and resources.

Pre-submission review

An independent pre-submission review gives your team a reviewer-style assessment of scientific logic, positioning, likely reviewer questions, and major vulnerabilities while there is still time to revise.

Summary-statement & resubmission strategy

Interpret reviewer feedback, distinguish fixable weaknesses from strategic problems, and decide whether to resubmit, redirect, or stop.

Strategic advisory

Ongoing scientific and strategic support for recurring funding decisions: which opportunities to pursue, when the company is ready, and how reviewer feedback should change the plan.

Approach

A rigorous process from
funding fit to decision.

Each engagement is organized around the decisions that make a non-dilutive funding application coherent: fit, evidence, product-development milestones, application logic, and reviewer readiness.

See the process